Thus, BC patients without PIK3CA or PTEN mutations (>50% of BC patients) may have an increased activation of the PAM pathway that could be targeted more effectively by a multi-node PAM inhibitor like gedatolisib than a single-node PAM or mutant-specific inhibitor. The gene discussed is PTEN; the disease is breast cancer.